Teva Pharmaceutical Industries (TEVA) Net Income towards Common Stockholders Growth (1y) (2010 - 2026)
Teva Pharmaceutical Industries (TEVA) Net Income towards Common Stockholders Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | -304.98% |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | -5.04% |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | -17.29% |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 7.59% |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | -2,482.61% |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 34.33% |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | 390.91% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Alkermes | 8.19 Bn | 7.53 Bn | 397.90 Mn | -99.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -304.98% |
| Mar 31, 2026 | 68.18% |
| Dec 31, 2025 | 270.91% |
| Sep 30, 2025 | 209.92% |
| Jun 30, 2025 | 132.08% |
| Mar 31, 2025 | -57.61% |
| Dec 31, 2024 | 84.69% |
| Sep 30, 2024 | -617.11% |
| Jun 30, 2024 | 3.42% |
| Mar 31, 2024 | 305.14% |
| Dec 31, 2023 | -34.63% |
| Sep 30, 2023 | 18.75% |
| Jun 30, 2023 | -226.26% |
| Mar 31, 2023 | 74.00% |
| Dec 31, 2022 | -783.44% |
| Sep 30, 2022 | -79.08% |
| Jun 30, 2022 | -232.38% |
| Mar 31, 2022 | -1,286.59% |
| Dec 31, 2021 | -200.67% |
| Sep 30, 2021 | 107.04% |